Dihexa

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is Dihexa?

Dihexa — formally named N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide and also known as PNB-0408 — is a synthetic, metabolically stable analog of angiotensin IV. It was designed by Joseph Harding’s laboratory at Washington State University as part of a programme exploring angiotensin IV derivatives for procognitive applications. Unlike natural angiotensin IV, which is rapidly degraded by peptidases, dihexa was engineered with modifications at both termini to resist enzymatic breakdown.

Key identifiers for the dihexa peptide include CAS number 1401708-83-5, molecular formula C₂₁H₃₃N₃O₄, and molecular weight 395.50 g/mol. It is covered by US Patent 8,673,848. The compound is classified as an HGF mimetic — a molecule that amplifies the activity of hepatocyte growth factor at its c-Met receptor, rather than directly activating the receptor itself.

It is essential to note that dihexa is not approved by the FDA or any regulatory agency for human use. It remains exclusively a research tool, and the published evidence base is extremely limited — consisting primarily of papers from the Harding laboratory at WSU, with minimal independent replication.

Mechanism of Action

The proposed dihexa mechanism centres on potentiation of the dihexa HGF/c-Met signalling pathway rather than direct receptor agonism. According to the originating research, dihexa binds to hepatocyte growth factor and stabilises its dimerisation, facilitating more effective engagement with the c-Met receptor on neurons. This is a fundamentally different approach from conventional neurotrophic peptides like BDNF or NGF, which bind directly to their own receptors.

In the primary research paper (McCoy et al., 2013), dihexa was reported to promote dendritic spine formation (spinogenesis) and dendritic branching in hippocampal neuron cultures. The compound was also reported to facilitate synaptogenesis — the formation of new synaptic connections — through downstream activation of c-Met signalling cascades including PI3K/Akt and MAPK/ERK pathways.

These molecular mechanisms are proposed to underlie dihexa cognitive effects observed in animal models. However, it must be noted that the key mechanistic paper (Benoist et al., 2014; PMID 25187433) linking dihexa’s procognitive effects to HGF/c-Met activation was retracted in 2025 by the Journal of Pharmacology and Experimental Therapeutics, and the original McCoy 2013 paper (PMID 23055539) received a formal expression of concern from the same journal. These retractions significantly weaken confidence in the proposed mechanism.

The HGF/c-Met Pathway

To understand the theoretical basis for dihexa, it helps to examine the HGF/c-Met pathway itself. Hepatocyte growth factor (HGF) — despite its liver-centric name — is expressed widely throughout the central nervous system. It acts through the c-Met receptor (also called MET), a receptor tyrosine kinase involved in cell survival, proliferation, motility, and morphogenesis.

In the brain, HGF/c-Met signalling has been implicated in neuroplasticity, neuronal survival, and synaptic function. Wright and Harding (2011) reviewed the role of the brain renin-angiotensin system and proposed that angiotensin IV’s cognitive effects were mediated through HGF/c-Met rather than traditional angiotensin receptors — a hypothesis that formed the intellectual foundation for dihexa’s development.

Wright and Harding (2015) further elaborated on the brain HGF/c-Met system as a potential therapeutic target for Alzheimer’s disease, arguing that compounds enhancing this pathway could promote neuronal repair and synaptogenesis in neurodegeneration. This remains a theoretical framework that has not been validated in human clinical trials.

Importantly, the HGF/c-Met pathway is also a well-established oncogenic signalling axis. Dysregulated c-Met activation is implicated in tumour growth, invasion, and metastasis across multiple cancer types. This creates a fundamental safety tension: any compound that potentiates HGF/c-Met signalling for neuroprotective purposes may simultaneously carry risks of promoting tumour development. This concern is discussed further in the safety section below. For contrast, neuroprotective peptides like Semax and Selank operate through entirely different mechanisms — primarily BDNF upregulation and GABAergic modulation — without engaging known oncogenic pathways.

Cognitive Enhancement Research

The primary evidence for dihexa as a cognitive enhancer comes from the McCoy et al. (2013) paper, which tested the compound in rats using the scopolamine-induced amnesia model and a bilateral hippocampal-cannulated spatial learning task. The researchers reported that dihexa restored spatial memory performance in scopolamine-treated animals and enhanced learning in normal aged rats when delivered both intracerebroventricularly and — notably — orally.

The claim of oral activity was significant because it suggested the compound could cross the blood-brain barrier, a major practical advantage over larger peptides. The researchers also reported that dihexa was effective at very low doses, which they attributed to its mechanism of potentiating endogenous HGF rather than acting as a direct agonist.

An independent systematic review by Ho and Nation (2018) examined the cognitive benefits of angiotensin IV and related analogs across published experimental studies. While this review covered the broader angiotensin IV field rather than dihexa specifically, it noted that angiotensin IV analogs showed procognitive effects in various memory paradigms. Critically, this review also highlighted the very limited number of research groups studying these compounds and the absence of clinical translation.

Wright and Harding (2019) published a subsequent review in the Journal of Alzheimer’s Disease summarising the brain renin-angiotensin system’s contributions to memory and cognition, including discussion of dihexa’s animal data. This review, however, comes from the same laboratory that developed the compound and does not constitute independent verification.

Alzheimer’s Disease Model Research

The Harding laboratory positioned dihexa as a potential anti-dementia agent, testing it in animal models relevant to Alzheimer’s disease. Wright and Harding (2015) reviewed the theoretical rationale for targeting HGF/c-Met in AD, arguing that deficits in this pathway contribute to synaptic loss — a hallmark of Alzheimer’s pathology that correlates more closely with cognitive decline than amyloid plaque burden.

Wright, Kawas, and Harding (2015) published a broader review in Progress in Neurobiology describing the development of small-molecule angiotensin IV analogs, including dihexa, for treating Alzheimer’s and Parkinson’s diseases. They reported that dihexa reversed cognitive deficits in aged rats and in scopolamine-treated models, framing these results as preclinical proof-of-concept.

However, no Alzheimer’s disease transgenic mouse studies or clinical trials in AD patients have been published. The preclinical data remains confined to pharmacological impairment models (scopolamine) and aged rats — models that have well-documented limitations in predicting clinical efficacy for neurodegenerative diseases. Decades of AD research have shown that compounds effective in these simpler models frequently fail in human trials. Peptides like Cerebrolysin, by comparison, have been tested in human AD patients — though even those results remain debated.

The “10 Million Times More Potent” Claim

Perhaps the most widely circulated claim about dihexa is that it is “ten million times more potent than BDNF” — a statement that requires careful contextualisation to avoid serious misinterpretation.

This claim originates from the McCoy et al. (2013) paper, where the researchers compared the effective concentrations of dihexa and BDNF required to promote dendritic branching in cultured hippocampal neurons. Dihexa reportedly showed activity at picomolar concentrations (10⁻¹² M), while BDNF required nanomolar concentrations (10⁻⁵ M range) — yielding an approximate 10⁷-fold difference in effective concentration for this specific in vitro assay.

Critical caveats that are almost always omitted from popular discussion:

• This is an in vitro comparison only — it reflects dendritic branching in a cell culture dish, not cognitive enhancement in a living organism.
• Dihexa and BDNF work through completely different mechanisms — dihexa potentiates HGF/c-Met while BDNF activates TrkB receptors. Comparing their potencies is like comparing the effective concentration of petrol and an electric charge for starting an engine.
• “More potent” does not mean “more effective” — a lower effective concentration tells you nothing about maximum efficacy, duration of effect, or clinical relevance.
• The comparison has not been independently replicated — it comes from a single experiment in a single paper from the developing laboratory.
• The paper carrying the claim has received a formal expression of concern from the publishing journal.

Responsible interpretation: dihexa appears to promote dendritic branching at much lower concentrations than BDNF in cell culture. Whether this translates to any meaningful cognitive advantage in a living organism — let alone a human — is entirely unknown.

Side Effects & Safety Concerns

There is no human safety data for dihexa. The compound has never been administered to humans in any clinical trial or formal safety study. Any discussion of dihexa side effects must therefore be framed around theoretical risks and the known biology of its target pathway.

The most significant theoretical concern is cancer risk. The HGF/c-Met pathway is one of the most well-characterised oncogenic signalling systems in cancer biology. Aberrant c-Met activation drives tumour growth, angiogenesis, invasion, and metastasis in cancers including lung, gastric, hepatocellular, renal, and breast carcinomas. Major pharmaceutical companies have invested billions in developing c-Met inhibitors as anti-cancer agents. A compound specifically designed to potentiate HGF/c-Met signalling therefore carries an inherent theoretical risk of promoting tumourigenesis, particularly with chronic exposure.

Notably, the Harding laboratory itself published work on HGF mimetics as potential anti-cancer agents (Kawas et al., 2011) — compounds designed to inhibit rather than potentiate c-Met. This illustrates the dual nature of the pathway: the same research group developed both activators (dihexa, for cognition) and inhibitors (for cancer) of the same system. However, this anti-cancer paper (PMID 21859930) was subsequently retracted in 2025.

Additional dihexa side effects concerns include:

• Unknown long-term neurotoxicity — chronic potentiation of any growth factor pathway could have unpredictable effects on neural architecture
• No established dose-response relationship in living organisms beyond limited animal data
• No drug interaction data
• No reproductive toxicity data
• Quality control uncertainty — as an unregulated research chemical, product purity and identity cannot be assumed

The absence of safety data is not evidence of safety. Given the oncogenic potential of its target pathway and the retraction of key supporting papers, the risk-benefit profile of dihexa is highly uncertain.

Pharmacokinetics

Dihexa was specifically engineered for metabolic stability. Unlike natural angiotensin IV (a tetrapeptide rapidly degraded by aminopeptidases), dihexa incorporates protective modifications — an N-terminal hexanoic acid cap and a C-terminal aminohexanoic amide extension — designed to resist enzymatic cleavage.

The McCoy et al. (2013) paper reported that dihexa was orally active in rats, suggesting meaningful absorption from the gastrointestinal tract and penetration across the blood-brain barrier (BBB). If confirmed, this would distinguish it from most peptide-based compounds, which typically require injection or intranasal delivery. However, formal pharmacokinetic parameters — including bioavailability, half-life, volume of distribution, and clearance — have not been published.

The compound’s small size (395.50 g/mol) and relatively lipophilic character are consistent with potential oral absorption and BBB penetration, but the absence of characterised pharmacokinetic data means its half-life remains unknown. No studies have examined dose-response relationships, tissue distribution, or metabolite profiles in any species.

Compound Profile

FAQ

What are the benefits of dihexa?

Proposed dihexa benefits are entirely based on animal and in vitro research. In rat studies, dihexa was reported to enhance spatial memory, reverse scopolamine-induced amnesia, and promote new synaptic connections through HGF/c-Met pathway potentiation. However, no human trials have confirmed any cognitive benefit, and key supporting papers have been retracted or flagged with expressions of concern. Any claimed benefits remain unverified hypotheses.

Is dihexa safe?

There is no human safety data for dihexa. The compound has never undergone clinical trials, formal toxicology assessment, or any regulatory safety review. The most significant theoretical concern is cancer risk, since the HGF/c-Met pathway it potentiates is a well-established oncogenic signalling system. Without safety data, no meaningful risk assessment can be made.

How does dihexa compare to other nootropic peptides?

Dihexa has the weakest evidence base of any commonly discussed nootropic peptide. Unlike Semax (approved in Russia, with multiple clinical studies) or Cerebrolysin (tested in thousands of human subjects), dihexa has never been administered to humans in any published study. Its mechanism — HGF/c-Met potentiation — is also unique among nootropic peptides, which carries both potential novelty and unknown risk.

Is dihexa really 10 million times more potent than BDNF?

This claim refers specifically to the concentration required to promote dendritic branching in hippocampal cell cultures — not to any measure of cognitive enhancement. Dihexa and BDNF act through entirely different receptor systems, making direct potency comparisons largely meaningless. The claim has not been independently replicated, and the paper it originates from has received a formal expression of concern.

Can dihexa be taken orally?

Animal studies reported oral activity for dihexa in rats, suggesting it may cross the blood-brain barrier when taken by mouth. However, formal pharmacokinetic data has not been published, and oral bioavailability has not been quantified. These are preliminary observations in rodents, not established pharmacological parameters.

What is PNB-0408?

PNB-0408 is the research designation for dihexa. The name derives from its development at the Pacific Northwest Biotechnology laboratory (the Harding lab’s commercial entity). The compound’s full chemical name is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, with CAS number 1401708-83-5.

Why have dihexa papers been retracted?

Several papers from the Harding laboratory have been retracted or flagged by the Journal of Pharmacology and Experimental Therapeutics. The Benoist et al. (2014) paper on dihexa’s procognitive and synaptogenic effects was retracted in 2025, and the McCoy et al. (2013) foundational paper received a formal expression of concern. Related papers on angiotensin IV analogs from the same group have also been retracted. These actions significantly undermine confidence in the published dihexa evidence base.

Is dihexa FDA approved?

No. Dihexa is not approved by the FDA, EMA, or any regulatory agency worldwide. It has never entered clinical trials in humans. It remains an early-stage research compound with no path to regulatory approval currently visible in the published literature.

References

1. McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-154. doi:10.1124/jpet.112.199497. PMID: 23055539. [Expression of concern issued]
2. Benoist CC, Kawas LH, Zhu M, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 2014;351(2):390-402. doi:10.1124/jpet.114.218735. PMID: 25187433. [Retracted 2025]
3. Wright JW, Harding JW. Brain renin-angiotensin—a new look at an old system. Prog Neurobiol. 2011;95(1):49-67. doi:10.1016/j.pneurobio.2011.07.001. PMID: 21777652.
4. Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer’s disease. J Alzheimers Dis. 2015;45(4):985-1000. doi:10.3233/JAD-142814. PMID: 25649658.
5. Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases. Prog Neurobiol. 2015;125:26-46. doi:10.1016/j.pneurobio.2014.11.004. PMID: 25455861.
6. Ho JK, Nation DA. Cognitive benefits of angiotensin IV and angiotensin-(1-7): a systematic review of experimental studies. Neurosci Biobehav Rev. 2018;92:209-225. doi:10.1016/j.neubiorev.2018.05.005. PMID: 29733881.
7. Wright JW, Harding JW. Contributions by the brain renin-angiotensin system to memory, cognition, and Alzheimer’s disease. J Alzheimers Dis. 2019;67(2):469-480. doi:10.3233/JAD-181035. PMID: 30664507.